Physician profile
Tauseef Sarguroh
NPI 1235442443
$143,814.04
in general payments reported to CMS, 2019-2025
37 companies · $88K in 2025
The $88K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $215 · 2021: $967 · 2022: $18K · 2023: $12K · 2024: $25K · 2025: $88K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $106K · Travel and Lodging: $9,215 · Food and Beverage: $8,440 · Consulting Fee: $1,349 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $105,528.88 |
| Travel and Lodging | $9,214.85 |
| Food and Beverage | $8,440.42 |
| Consulting Fee | $1,349.34 |
| Education | $205.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $70,199.77 | 2021-2025 | |
| Novo Nordisk INC | $67,136.34 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $842.42 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $788.03 | 2020-2025 | Acthar |
| Amgen INC. | $556.76 | 2021-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $379.62 | 2019-2025 | Rayaldee |
| Ani Pharmaceuticals, INC. | $378.12 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $346.15 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $318.56 | 2020-2025 | Jynarque |
| Vifor Pharma, INC. | $314.43 | 2021-2025 | Veltassa |
| Akebia Therapeutics INC | $256.66 | 2019-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $238.45 | 2019-2025 | |
| Fresenius USA Marketing, INC. | $214.12 | 2022-2024 | Velphoro |
| Ardelyx, INC. | $198.18 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.94 | 2022-2025 | Jardiance |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tauseef Sarguroh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.